Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis

被引:7
作者
Sousa-Pinto, Bernardo [1 ,2 ]
Vieira, Rafael Jose [1 ,2 ]
Brozek, Jan [5 ,6 ]
Cardoso-Fernandes, Antonio [1 ,2 ]
Lourenco-Silva, Nuno [1 ,2 ]
Ferreira-da-Silva, Renato [1 ,2 ]
Ferreira, Andre [2 ,3 ,4 ]
Gil-Mata, Sara [1 ,2 ]
Bedbrook, Anna [7 ]
Klimek, Ludger [8 ,9 ,10 ]
Fonseca, Joao A. [1 ,2 ]
Zuberbier, Torsten [11 ,12 ,13 ,14 ]
Schuenemann, Holger J.
Bousquet, Jean [11 ,12 ,13 ,14 ]
机构
[1] Univ Porto, Hlth Res Network, Ctr Hlth Technol & Serv Res, CINTESISRISE, Porto, Portugal
[2] Univ Porto, Dept Community Med Informat & Hlth Decis Sci, MEDCIDS, Porto, Portugal
[3] Univ Porto, Fac Med, Dept Biomed, Unit Anat, Porto, Portugal
[4] CHU Porto, Dept Ophthalmol, Porto, Portugal
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[6] McMaster Univ, Dept Med, Hamilton, ON, Canada
[7] MASK Air SAS, Montpellier, France
[8] ARIA, Montpellier, France
[9] Univ Med Mainz, Dept Otolaryngol Head & Neck Surg, Mainz, Germany
[10] Ctr Rhinol & Allergol, Wiesbaden, Germany
[11] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[12] Free Univ Berlin, Berlin, Germany
[13] Humboldt Univ, Berlin, Germany
[14] Fraunhofer Inst Translat Med & Pharmacol Immunol &, Berlin, Germany
关键词
Allergic rhinitis; intranasal antihistamines; intranasal corticosteroids; meta-analysis; systematic review; AQUEOUS NASAL SPRAY; DAILY FLUTICASONE PROPIONATE; PLACEBO-CONTROLLED TRIAL; ONCE-DAILY TREATMENT; QUALITY-OF-LIFE; OPTIMAL DOSE SELECTION; LONG-TERM SAFETY; MOMETASONE FUROATE; BECLOMETHASONE DIPROPIONATE; TRIAMCINOLONE ACETONIDE;
D O I
10.1016/j.jaci.2024.04.016
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: There is insufficient systematized evidence on the effectiveness of individual intranasal medications in allergic rhinitis (AR). Objectives: We sought to perform a systematic review to compare the efficacy of individual intranasal corticosteroids and antihistamines against placebo in improving the nasal and ocular symptoms and the rhinoconjunctivitis-related quality of life of patients with perennial or seasonal AR. Methods: The investigators searched 4 electronic bibliographic databases and 3 clinical trials databases for randomized controlled trials (1) assessing adult patients with seasonal or perennial AR and (2) comparing the use of intranasal corticosteroids or antihistamines versus placebo. Assessed outcomes included the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of- Life Questionnaire. The investigators performed random-effects meta-analyses of mean differences for each medication and outcome. The investigators assessed evidence certainty using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. Results: This review included 151 primary studies, most of which assessed patients with seasonal AR and displayed unclear or high risk of bias. Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improvements in the Total Nasal Symptom Score and Rhinoconjunctivitis Quality-of-Life Questionnaire. Azelastine-fluticasone displayed the highest probability of resulting in moderate or large improvements of Total Ocular Symptom Score. Overall, evidence certainty was considered "high"in 6 of 46 analyses, "moderate"in 23 of 46 analyses, and "low"/"very low"in 17 of 46 analyses. Conclusions: Most intranasal medications are effective in improving rhinitis symptoms and quality of life. However, there are relevant differences in the associated evidence certainty.
引用
收藏
页码:340 / 354
页数:15
相关论文
共 161 条
[31]  
classic.clinicaltrials, NCT00358527-Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608)
[32]  
classic.clinicaltrials, NCT01279057-A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
[33]  
classic.clinicaltrials, NCT01038427-A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
[34]  
classic.clinicaltrials, NCT01033825-A 6-Week Randomized, Double-Blind, Placebo-Controlled, Par- allel Group, Safety and Efficacy Study of the Potential Inhibitory Effects on the Hypothalamic-Pituitary-Adrenal Axis of Ciclesonide HFA Nasal Aerosol and Ci- clesonide Aqueous Nasal Spray in Subjects 12 Years and Older With Perennial Allergic Rhinitis
[35]  
classic.clinicaltrials, R1810221-An efficacy and safety study of fluticasone propionate (FP) aqueous nasal spray in subjects with seasonal allergic rhinitis (SAR)
[36]  
classic.clinicaltrials, NCT03855189-Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)
[37]  
classic.clinicaltrials, NCT03882047-Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE in Seasonal Allergic Rhinitis Patients (I94-001)
[38]  
classic.clinicaltrials, NCT00618332-Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?
[39]  
classic.clinicaltrials, NCT00719862-A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
[40]  
classic.clinicaltrials, NCT00453063-Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)